Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;95(1):4-9.
doi: 10.1002/ajh.25657. Epub 2019 Oct 29.

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

Abdullah S Al Saleh  1   2 , M Hasib Sidiqi  1 , Angela Dispenzieri  1 , Prashant Kapoor  1 , Eli Muchtar  1 , Francis K Buadi  1 , Rahma Warsame  1 , Martha Q Lacy  1 , David Dingli  1 , Nelson Leung  1   3 , Wilson I Gonsalves  1 , Taxiarchis V Kourelis  1 , Morie A Gertz  1 , Ronald S Go  1 , Robert A Kyle  1 , S Vincent Rajkumar  1 , Shaji K Kumar  1
Affiliations

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

Abdullah S Al Saleh et al. Am J Hematol. 2020 Jan.

Abstract

Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 109 /L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P < .001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P < .0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P < .0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P < .0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P = .006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors report no relevant financial conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Progression-free survival (A) and overall survival (B) based on the hematopoietic score. PFS, progression-free survival; OS, overall survival
See this image and copyright information in PMC

References

    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. - PubMed
    1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3): 842–854. - PubMed
    1. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. - PubMed
    1. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. - PMC - PubMed
    1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1): 21–33. - PubMed